199 related articles for article (PubMed ID: 26872382)
1. The E1B19K-deleted oncolytic adenovirus mutant AdΔ19K sensitizes pancreatic cancer cells to drug-induced DNA-damage by down-regulating Claspin and Mre11.
Pantelidou C; Cherubini G; Lemoine NR; Halldén G
Oncotarget; 2016 Mar; 7(13):15703-24. PubMed ID: 26872382
[TBL] [Abstract][Full Text] [Related]
2. Oncolytic adenoviral mutants with E1B19K gene deletions enhance gemcitabine-induced apoptosis in pancreatic carcinoma cells and anti-tumor efficacy in vivo.
Leitner S; Sweeney K; Oberg D; Davies D; Miranda E; Lemoine NR; Halldén G
Clin Cancer Res; 2009 Mar; 15(5):1730-40. PubMed ID: 19223497
[TBL] [Abstract][Full Text] [Related]
3. The oncolytic adenovirus AdΔΔ enhances selective cancer cell killing in combination with DNA-damaging drugs in pancreatic cancer models.
Cherubini G; Kallin C; Mozetic A; Hammaren-Busch K; Müller H; Lemoine NR; Halldén G
Gene Ther; 2011 Dec; 18(12):1157-65. PubMed ID: 21975464
[TBL] [Abstract][Full Text] [Related]
4. Survivin silencing and TRAIL expression using oncolytic adenovirus increase anti-tumorigenic activity in gemcitabine-resistant pancreatic cancer cells.
Han Z; Lee S; Je S; Eom CY; Choi HJ; Song JJ; Kim JH
Apoptosis; 2016 Mar; 21(3):351-64. PubMed ID: 26677013
[TBL] [Abstract][Full Text] [Related]
5. Advances in oncolytic adenovirus therapy for pancreatic cancer.
Nattress CB; Halldén G
Cancer Lett; 2018 Oct; 434():56-69. PubMed ID: 29981812
[TBL] [Abstract][Full Text] [Related]
6. An oncolytic adenovirus defective in pRb-binding (dl922-947) can efficiently eliminate pancreatic cancer cells and tumors in vivo in combination with 5-FU or gemcitabine.
Bhattacharyya M; Francis J; Eddouadi A; Lemoine NR; Halldén G
Cancer Gene Ther; 2011 Oct; 18(10):734-43. PubMed ID: 21836633
[TBL] [Abstract][Full Text] [Related]
7. AduPARE1A and gemcitabine combined treatment trigger synergistic antitumor effects in pancreatic cancer through NF-κB mediated uPAR activation.
Maliandi MV; Mato-Berciano A; Sobrevals L; Roué G; José A; Fillat C
Mol Cancer; 2015 Jul; 14():146. PubMed ID: 26227809
[TBL] [Abstract][Full Text] [Related]
8. Improved potency and selectivity of an oncolytic E1ACR2 and E1B19K deleted adenoviral mutant in prostate and pancreatic cancers.
Oberg D; Yanover E; Adam V; Sweeney K; Costas C; Lemoine NR; Halldén G
Clin Cancer Res; 2010 Jan; 16(2):541-53. PubMed ID: 20068104
[TBL] [Abstract][Full Text] [Related]
9. Downregulation of Mcl-1 synergizes the apoptotic response to combined treatment with cisplatin and a novel fiber chimeric oncolytic adenovirus.
You L; Wang Y; Jin Y; Qian W
Oncol Rep; 2012 Apr; 27(4):971-8. PubMed ID: 22266706
[TBL] [Abstract][Full Text] [Related]
10. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
11. Optimisation of replication-selective oncolytic adenoviral mutants in combination with chemotherapeutics.
Halldén G
J BUON; 2009 Sep; 14 Suppl 1():S61-7. PubMed ID: 19785071
[TBL] [Abstract][Full Text] [Related]
12. CHK1 inhibition sensitizes pancreatic cancer cells to gemcitabine via promoting CDK-dependent DNA damage and ribonucleotide reductase downregulation.
Liang M; Zhao T; Ma L; Guo Y
Oncol Rep; 2018 Mar; 39(3):1322-1330. PubMed ID: 29286153
[TBL] [Abstract][Full Text] [Related]
13. Synergistic antitumor effect of adenovirus armed with Drosophila melanogaster deoxyribonucleoside kinase and nucleoside analogs for human breast carcinoma in vitro and in vivo.
Tang M; Zu C; He A; Wang W; Chen B; Zheng X
Drug Des Devel Ther; 2015; 9():3301-12. PubMed ID: 26203222
[TBL] [Abstract][Full Text] [Related]
14. Oncolytic adenovirus expressing relaxin (YDC002) enhances therapeutic efficacy of gemcitabine against pancreatic cancer.
Jung KH; Choi IK; Lee HS; Yan HH; Son MK; Ahn HM; Hong J; Yun CO; Hong SS
Cancer Lett; 2017 Jun; 396():155-166. PubMed ID: 28315430
[TBL] [Abstract][Full Text] [Related]
15. Potent antitumor effect of neurotensin receptor-targeted oncolytic adenovirus co-expressing decorin and Wnt antagonist in an orthotopic pancreatic tumor model.
Na Y; Choi JW; Kasala D; Hong J; Oh E; Li Y; Jung SJ; Kim SW; Yun CO
J Control Release; 2015 Dec; 220(Pt B):766-82. PubMed ID: 26471393
[TBL] [Abstract][Full Text] [Related]
16. Parainfluenza Virus Infection Sensitizes Cancer Cells to DNA-Damaging Agents: Implications for Oncolytic Virus Therapy.
Fox CR; Parks GD
J Virol; 2018 Apr; 92(7):. PubMed ID: 29343567
[TBL] [Abstract][Full Text] [Related]
17. A NOTCH-sensitive uPAR-regulated oncolytic adenovirus effectively suppresses pancreatic tumor growth and triggers synergistic anticancer effects with gemcitabine and nab-paclitaxel.
Mato-Berciano A; Raimondi G; Maliandi MV; Alemany R; Montoliu L; Fillat C
Oncotarget; 2017 Apr; 8(14):22700-22715. PubMed ID: 28186974
[TBL] [Abstract][Full Text] [Related]
18. Engineered adenoviruses combine enhanced oncolysis with improved virus production by mesenchymal stromal carrier cells.
Hammer K; Kazcorowski A; Liu L; Behr M; Schemmer P; Herr I; Nettelbeck DM
Int J Cancer; 2015 Aug; 137(4):978-90. PubMed ID: 25604186
[TBL] [Abstract][Full Text] [Related]
19. Mre11 inhibition by oncolytic adenovirus associates with autophagy and underlies synergy with ionizing radiation.
Rajecki M; af Hällström T; Hakkarainen T; Nokisalmi P; Hautaniemi S; Nieminen AI; Tenhunen M; Rantanen V; Desmond RA; Chen DT; Guse K; Stenman UH; Gargini R; Kapanen M; Klefström J; Kanerva A; Pesonen S; Ahtiainen L; Hemminki A
Int J Cancer; 2009 Nov; 125(10):2441-9. PubMed ID: 19672857
[TBL] [Abstract][Full Text] [Related]
20. Polo-like kinase 1 activated by the hepatitis B virus X protein attenuates both the DNA damage checkpoint and DNA repair resulting in partial polyploidy.
Studach L; Wang WH; Weber G; Tang J; Hullinger RL; Malbrue R; Liu X; Andrisani O
J Biol Chem; 2010 Sep; 285(39):30282-93. PubMed ID: 20624918
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]